



(22) Date de dépôt/Filing Date: 1996/11/12

(41) Mise à la disp. pub./Open to Public Insp.: 1997/05/22

(45) Date de délivrance/Issue Date: 2006/05/23

(62) Demande originale/Original Application: 2 237 263

(30) Priorité/Priority: 1995/11/13 (US08/557,955)

(51) Cl.Int./Int.Cl. *C07H 23/00* (2006.01),
A61P 35/00 (2006.01), *A61K 51/00* (2006.01)


(72) Inventeurs/Inventors:
COLLINS, DOUGLAS A., US;
HOGENKAMP, HENRICUS PETRUS CORNELIS, US

(73) Propriétaires/Owners:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND
RESEARCH, US;
THE REGENTS OF THE UNIVERSITY OF MINNESOTA,
US

(74) Agent: GOUDREAU GAGE DUBUC

(54) Titre : MARQUAGE AUX RADIONUCLEIDES DE VITAMINE B₁₂ ET DE SES COENZYMES

(54) Title: RADIONUCLIDE LABELING OF VITAMIN B₁₂ AND COENZYMES THEREOF



(57) Abrégé/Abstract:

A compound useful for in vivo imaging of organs and tumors is provided of formula (1) wherein (a) is cobalamin, (b) derived from a corrin carboxylic acid group of said cobalamin, Y is a linking group and X is a chelating group, optionally comprising a detectable radionuclide or a paramagnetic metal ion, and n is 1-3.

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07H 23/00, A61K 51/00	A1	(11) International Publication Number: WO 97/18231 (43) International Publication Date: 22 May 1997 (22.05.97)
(21) International Application Number: PCT/US96/18334 (22) International Filing Date: 12 November 1996 (12.11.96) (30) Priority Data: 08/557,955 13 November 1995 (13.11.95) US (71) Applicants (for all designated States except US): MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH [US/US]; 200 First Street, S.W., Rochester, MN 55905 (US). REGENTS OF THE UNIVERSITY OF MINNESOTA [US/US]; Morrill Hall, 100 Church Street, S.E., Minneapolis, MN 55455 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): COLLINS, Douglas, A. [US/US]; 1150 Meadowlark Court, S.W., Rochester, MN 55902 (US). HOGENKAMP, Henricus, P., C. [US/US]; 2211 Marion Road, Roseville, MN 55113 (US). (74) Agent: VIKSNINS, Ann, S.; Schwegman, Lundberg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN 55402 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>		
(54) Title: RADIONUCLIDE LABELING OF VITAMIN B ₁₂ AND COENZYMES THEREOF (57) Abstract A compound useful for <i>in vivo</i> imaging of organs and tumors is provided of formula (1) wherein (a) is cobalamin, (b) derived from a corrin carboxylic acid group of said cobalamin, Y is a linking group and X is a chelating group, optionally comprising a detectable radionuclide or a paramagnetic metal ion, and n is 1-3. $\begin{array}{c} \text{X} \\ \\ [\text{Co}] - [\text{C} - \text{Y} - \text{X}]_n \\ \\ \text{O} \end{array} \quad (1)$ $\begin{array}{c} \text{X} \\ \\ [\text{Co}] \\ \\ \text{O} \end{array} \quad (a)$ $\begin{array}{c} \text{O} \\ \\ \text{C} \end{array} \quad (b)$		


RADIONUCLIDE LABELING OF VITAMIN B₁₂
AND COENZYMES THEREOF

5

Background of the Invention

For several years after the isolation of vitamin B₁₂ as cyanocobalamin in 1948, it was assumed that cyanocobalamin and possibly hydroxocobalamin, its photolytic breakdown product, occurred in man. Since
10 then it has been recognized that cyanocobalamin is an artifact of the isolation of vitamin B₁₂ and that hydroxocobalamin and the two coenzyme forms, methylcobalamin and adenosylcobalamin, are the naturally occurring forms of the vitamin.

The structure of these various forms is shown in Figure 1,
15 wherein X is CN, OH, CH₃ or adenosyl, respectively. Hereinafter, the term cobalamin will be used to refer to all of the molecule except the X group. The fundamental ring system without cobalt (Co) or side chains is called *corrin* and the octadehydrocorrin is called *corrole*. The Co-contg heptacarboxylic acid resulting from hydrolysis of all the amide groups without the CN and the
20 nucleotide, is designated *cobyrinic acid*. The corresponding hexacarboxylic acid with D-1-amino-2-propanol side chain f is called *cobinic acid* and the hexacarboxylic acid with the α -D-ribofuranose-3-phosphate attached to the 2-position of the amino propanol is called *cobamic acid*. Thus, *cobamide* is the hexaamide of cobamic acid, *cobyric acid* is the hexaamide of cobyrinic acid and
25 *cobinamide* is the hexaamide of cobinic acid. Figure 1 is adapted from The Merck Index, Merck & Co. (11th ed. 1989), wherein X is above the plane defined by the corrin ring and nucleotide is below the plane of the ring. The corrin ring has attached six amidoalkyl (H₂NC(O)Alk) substituents, at the 2, 3, 7, 8, 13, and 18 positions, which can be designated a-e and g, respectively. See
30 D.L. Anton et al., J. Amer. Chem. Soc., 102, 2215 (1980). The molecule shown in Figure 1 can be abbreviated as shown below:



5

wherein, e.g., X is CN, OH, CH₃, or adenosyl.

Methylcobalamin serves as the cytoplasmic coenzyme for ⁵N-methyltetrahydrofolate:homocysteine methyl transferase (methionine synthetase, EC 2.1.1.13), which catalyzes the formation of methionine from homocysteine.

10 Adenosylcobalamin is the mitochondrial coenzyme for methylmalonyl CoA mutase (EC5.4.99.2) which interconverts methylmalonyl CoA and succinyl CoA.

All forms of vitamin B₁₂ (adenosyl-, cyano-, hydroxo-, or methylcobalamin) must be bound by the transport proteins, Intrinsic Factor and Transcobalamin II to be biologically active. Specifically, gastrointestinal
15 absorption of vitamin B₁₂ relies upon the intrinsic factor-vitamin B₁₂ complex being bound by the intrinsic factor receptors in the terminal ileum. Likewise, intravascular transport and subsequent cellular uptake of vitamin B₁₂ throughout the body is dependent upon transcobalamin II and the cell membrane
20 transcobalamin II receptors, respectively. After the transcobalamin II-vitamin B₁₂ complex has been internalized, the transport protein undergoes lysozymal degradation, which releases vitamin B₁₂ into the cytoplasm. All forms of vitamin B₁₂ can then be interconverted into adenosyl-, hydroxo-, or methylcobalamin depending upon cellular demand. See, for example, A.E. Finkler et al., Arch. Biochem. Biophys., 120, 79 (1967); C. Hall et al., J. Cell Physiol., 133, 187
25 (1987); M.E. Rappazzo et al., J. Clin. Invest., 51, 1915 (1972) and R. Soda et al., Blood, 65, 795 (1985).

Cells undergoing rapid proliferation have been shown to have increased uptake of thymidine and methionine. (See, for example, M.E. van
30 Eijkeren et al., Acta Oncologica, 31, 539 (1992); K. Kobota et al., J. Nucl. Med., 32, 2118 (1991) and K. Higashi et al., J. Nucl. Med., 34, 773 (1993)). Since

methylocobalamin is directly involved with methionine synthesis and indirectly involved in the synthesis of thymidylate and DNA, it is not surprising that methylocobalamin as well as Cobalt-57-cyanocobalamin have also been shown to have increased uptake in rapidly dividing tissue (for example, see, B.A. Cooper et al., Nature, 191, 393 (1961); H. Flodh, Acta Radiol. Suppl., 284, 55 (1968); L. Bloomquist et al., Experientia, 25, 294 (1969)). Additionally, upregulation in the number of transcobalamin II receptors has been demonstrated in several malignant cell lines during their accelerated thymidine incorporation and DNA synthesis (see, J. Lindemans et al., Exp. Cell. Res., 184, 449 (1989); T. Amagasaki et al., Blood, 26, 138 (1990) and J.A. Begly et al., J. Cell Physiol., 156, 43 (1993).

Vitamin B₁₂ has several characteristics which potentially make it an attractive *in vivo* tumor imaging agent. Vitamin B₁₂ is water soluble, has no known toxicity, and in excess is excreted by glomerular filtration. In addition, the uptake of vitamin B₁₂ could potentially be manipulated by the administration of nitrous oxide and other pharmacological agents (D. Swanson et al., Pharmaceuticals in Medical Imaging, MacMillan Pub. Co., NY (1990) at pages 621-628).

Bacteria naturally insert Cobalt-59 into the corrin ring of vitamin B₁₂. Commercially this has been exploited by the fermentative production of Co-56, Co-57, Co-58, and Co-60 radiolabeled vitamin B₁₂. For example, see Chalet et al., Science, 111, 601 (1950). Unfortunately Cobalt-57, with a half life of 270.9 days, makes Co-57-cyanocobalamin unsuitable for clinical tumor imaging. Other metal ions (cobalt, copper and zinc) have been chemically inserted into naturally occurring descobaltocorrinoids produced by *Chromatium* and *Streptomyces olivaceous*. Attempts to chemically insert other metal ions in these cobalt free corrinoid rings has been unsuccessful. The placement of metals (cobalt, nickel, palladium, platinum, rhodium, zinc, and lithium) into a synthetic corrin ring has not presented any major difficulties. However, their instability and cost to produce makes them impractical for biological assays. Although Co-59 is a weakly paramagnetic quadrupolar nuclei in the 2⁺ oxidation state,


Co-59 exists in the 3⁺ oxidation state within the corrin ring of vitamin B₁₂ and is diamagnetic. Therefore, insertion of either a radioactive or paramagnetic metal ion other than cobalt into the corrin ring does not seem feasible at this time.

A process for preparing ¹²⁵I-vitamin B₁₂ derivatives is described in Niswender et al. (U.S. Pat. No. 3,981,863). In this process, vitamin B₁₂ is first subjected to mild hydrolysis to form a mixture of monocarboxylic acids, which Houts, *infra*, disclosed to contain mostly the (e)-isomer. The mixture is then reacted with a p-(aminoalkyl)phenol to introduce a phenol group into the B₁₂ acids (via reaction with one of the free carboxylic acid groups). The mixed substituent B₁₂ derivatives are then iodinated in the phenol-group substituent. This U.S. patent teaches that the mixed ¹²⁵I-B₁₂ derivatives so made are useful in the radioimmunoassay of B₁₂, using antibodies raised against the mixture.

T. M. Houts (U.S. Pat. No. 4,465,775) reported that the components of the radiolabelled mixture of Niswender et al. did not bind with equal affinity to IF. Houts disclosed that radioiodinated derivatives of the pure monocarboxylic (d)-isomer are useful in assays of B₁₂ in which IF is used. However, although Houts generally discloses that the monocarboxylic (d)-isomer can be labelled with fluorophores or enzymes and used in competitive assays for vitamin B₁₂ in fluids, a continuing need exists for labelled vitamin B₁₂ derivatives suitable for tumor and organ imaging and therapy.

Summary of the Invention

The present invention provides detectable compounds of the general formula (I):



wherein the moiety $\begin{array}{c} \text{X} \\ | \\ [\text{Co}] \\ | \end{array}$ is cobalamin, X is CN, OH, methyl or adenosyl, $\begin{array}{c} \text{O} \\ || \\ \text{C} \end{array}$

is the residue of a monocarboxylic acid of the cobalamin, derived from a corrin propionamide group, and is preferably the essentially pure (b)-, (d)-, or (e)-monocarboxylic acid; Y is a linking group and Det is a chelating group comprising a detectable metal, such as a radionuclide or paramagnetic metal ion.

5 Preferably, the linking group is $-N(H)(CH_2)_{2-6}NH-$.

For example, compounds of formula (I) derived from the (b)-monocarboxylic acid, wherein Det is the diethylenetriaminepentaacetic acid group (DTPA), were prepared comprising Tc-99m, In-111 and Gd-153. These compounds were found to be readily absorbed through the mammalian peritoneal
10 membrane and gastrointestinal tract, to localize within the liver, kidney, pancreas, and spleen. Therefore, the present compounds can be used to evaluate hepatic, splenic, renal, pancreatic, and small bowel function in mammals such as humans and experimental animals, by administering a compound of formula (I) to the mammal and detecting its presence in the target organ, using appropriate
15 normal control values for comparison.

Certain neoplastic tissue has been found to act as a vitamin B₁₂ sink, accumulating the vitamin to a greater extent than the surrounding slower dividing tissue. Therefore, the present compounds can also be used for tumor imaging and/or targeted cancer therapy, by administering a compound of
20 formula (I) to a mammal afflicted with a tumor, so that the compound localizes in the tumor, and optionally, detecting the presence of the compound in the tumor, particularly tumors of the organs listed above.

Intermediates useful in the preparation of the compounds of formula (I) are also an aspect of the invention, including compounds wherein
25 Det is replaced by Chel, which is an organic chelating group, or chelator, capable of chelating a radionuclide or radioisotope.

Brief Description of the Figures

Figure 1 depicts the structure of vitamin B₁₂, wherein X is CN
30 (cyano), OH, CH₃ or adenosyl.

AMENDED SHEET

Figure 2 schematically depicts the synthesis of a cobalamin metal ion DTPA complex.

Detailed Description of the Invention


5 The compounds of formula I can be prepared by producing a monocarboxylic acid of X-[cobalamin], wherein X is cyano-, methyl, adenosyl, and the like. These compounds can be prepared by the mild acid hydrolysis of cyanocobalamin, which has been shown to yield a mixture of mono-, a dicarboxylic acids and one tricarboxylic acid. These carboxylic acids are derived
10 from the propionamide side chains designated b, d and e, as discussed hereinabove, which are more susceptible to hydrolysis than the amide groups on acetamide side chains a, c, and g. The (b)-, (d)-, and (e)-monocarboxylic acids can be separated by column chromatography. See Figure 1 herein, and Figure 1 of D.L. Anton et al., J. Amer. Chem. Soc., 102, 2215 (1980). See, also, J.B.
15 Armitage et al., J. Chem. Soc., 3349 (1953); K. Bernhauer, Biochem. Z., 344, 289 (1966); H.P.C. Hogenkamp et al., Biochemistry, 14, 3707 (1975); and L. Ellenbogen, in "Cobalamin," Biochem. and Pathophysiol., B. Babior, ed., Wiley, N.Y. (1975) at chapter 5.

 The X-[cobalamin] [CO₂H] can be linked to the metal chelator by
20 means of a linking group, which is preferably a divalent, or "bifunctional" organic linking group. Such linking groups comprise two reactive groups, one that is coupled to the CO₂H group, and the other that is coupled to the metal chelator. A variety of homobifunctional and heterobifunctional linking reagents known in the art are useful in the present invention. Preferred linkers comprise
25 one or two amino or hydroxyl groups, such as ω -aminoalkanoic acids, e.g., ϵ -amino caproic acid (H₂N-(CH₂)₅-COOH), or alkane diamines including 1,4-diaminobutane, 1, 5-diaminopentane and 1,6-diaminohexane, and the like. Particularly preferred among the aminoalkanoic acids and similar compounds are those which are soluble in aqueous buffers.

30 Det is a chelating group comprising a radionuclide, such as a metallic radioisotope. Preferred among these chelating compounds "chelators"


or (chel) are such polycarboxylic acids as EDTA (ethylenediaminetetraacetic acid), DTPA, DCTA, DOTA, TETA, or analogs or homologs thereof.

DTPA (diethylenetriaminepentaacetic acid) can be attached to cobalamin carboxylic acid(s) via reaction of diethylenetriaminepentaacetic dianhydride (Aldrich Chem. Co.) with a linker comprising a free amino group. This yields a Chel group that is 2-(amidomethyl)-1,1,7,7-diethylenetriaminetetraacetic acid. This chelator can be reacted with radionuclides to yield a Det moiety of the general formula



wherein M is the radionuclide. The synthetic route to a cobalamin metal ion DTPA complex (4) is schematically shown in Figure 2, wherein WSC = water soluble carbodiimide.

The chelator (chel) DCTA has the general formula:



DCTA is a cyclohexane-based metal chelator, wherein R^3 may be (C_1-C_4) alkyl or $CH_2CO_2^-$, which may be attached to the Y through positions 4 or 5, or through the group R^3 and which carries from 1 to 4 detectable metal or nonmetal cations (M), monovalent cations, or the alkaline earth metals. Thus, with metals of oxidation state +1, each individual cyclohexane-based molecule

may carry up to 4 metal cations (where both R³ groups are CH₂COOM). As is more likely, with higher oxidation states, the number of metals will decrease to 2 or even 1 per cyclohexane skeleton. This formula is not intended to limit the molecule to any specific stereochemistry. In particular, both amino

5 functionalities may be either cis or trans to each other.

Other macrocyclic carboxylic acid chelators which can be linked to the cobalamin carboxylic acid via bis-amino linking groups include TETA 1,4,8,11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid; 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA); 1,4,8,12-
 10 tetraazacyclopentadecane-N,N',N'',N'''-tetraacetic acid (15N4); 1,4,7-triazacyclononane-N,N',N''-triacetic acid (9N3); and 1,5,9-triazacyclododecane-N,N',N''-triacetic acid (12N3). Bifunctional chelators based on macrocyclic ligands in which conjugation is via an activated arm attached to the carbon backbone of the ligand can be employed as described by M. Moi et al., J. Amer. Chem. Soc., 49, 2639 (1989) (2-p-nitrobenzyl-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid); S.V. Deshpande et al., J. Nucl. Med., 31, 473 (1990); G. Ruser et al., Bioconj. Chem., 1, 345 (1990); C.J. Broan et al., J. C. S. Chem. Comm., 23, 1739 (1990); and C.J. Anderson et al., J. Nucl. Med., 36, 850 (1995) (6-bromoacetamido-benzyl-1,4,8,11-tetraazacyclotetradecane-
 20 N,N',N'',N'''-tetraacetic acid (BAT)).

Any metal capable of being detected in a diagnostic procedure *in vivo* or *in vitro* can be employed as M in the Det moieties. Particularly, any radioactive metal ion capable of producing a diagnostic result in a human or animal body or in an *in vitro* diagnostic assay may be used in the practice of the
 25 present invention. Suitable ions include the following: Antimony-124, Antimony-125, Arsenic-74, Barium-103, Barium-140, Beryllium-7, Bismuth-206, Bismuth-207, Cadmium-109, Cadmium-115m, Calcium-45, Cerium-139, Cerium-141, Cerium-144, Cesium-137, Chromium-51, Cobalt-56, Cobalt-57, Cobalt-58, Cobalt-60, Cobalt-64, Erbium-169, Europium-152, Gadolinium-153,
 30 Gold-195, Gold-199, Hafnium-175, Hafnium-175-181, Indium-111, Iridium-192, Iron-55, Iron-59, Krypton-85, Lead-210, Manganese-54, Mercury-197,

Mercury-203, Molybdenum-99, Neodymium-147, Neptunium-237, Nickel-63,
 Niobium-95, Osmium-185 + 191, Palladium-103, Platinum-195m,
 Praseodymium-143, Promethium-147, Protactinium-233, Radium-226,
 Rhenium-186, Rubidium-86, Ruthenium-103, Ruthenium-106, Scandium-44,
 5 Scandium-46, Selenium-75, Silver-110m, Silver-111, Sodium-22, Strontium-85,
 Strontium-89, Strontium-90, Sulfur-35, Tantalum-182, Technetium-99m,
 Tellurium-125, Tellurium-132, Thallium-204, Thorium-228, Thorium-232,
 Thallium-170, Tin-113, Titanium-44, Tungsten-185, Vanadium-48, Vanadium-
 49, Ytterbium-169, Yttrium-88, Yttrium-90, Yttrium-91, Zinc-65, and
 10 Zirconium-95.

The compounds of formula (I) are preferable dissolved or
 dispersed in a nontoxic liquid vehicle, such as physiological saline or a similar
 aqueous vehicle, to the desired concentration. A preselected analytical,
 diagnostic or therapeutic unit dose is then administered to the test animal or
 15 human patient, by oral administration or ingestion or by parenteral
 administration, as by intravenous or intraperitoneal infusion or injection, to
 attain the desired *in vivo* concentration. Doses useful for imaging or treating
 human organs or tumors can be derived, from those found to be effective to
 image or treat organs in humans *in vitro* or in animal models, such as those
 20 described hereinbelow, or from dosages of other labelled vitamin B₁₂ molecules,
 previously employed in animal therapy or imaging.

The invention will be further described by reference to the
 following detailed examples, wherein cyanocobalamin and 1-ethyl-3-(3-
 dimethylaminopropyl) carbodiimide were purchased from Sigma Chem. Co., St.
 25 Louis, MO. Adenosine, 1,4-diaminobutane dihydrochloride, diethylenetriamine
 pentaacetic (DPTA), hexamethylphosphoramide, 1-hydroxybenzotriazole
 hydrate, iodomethane and thionylchloride were obtained from Aldrich Chem.
 Co., Milwaukee, WI. Thin layer chromatography (TLC) silica gel and PET-
 cellulose sheets were purchased from E. M. Science, Gibbstown, NJ. Tc^{99m} and
 30 In¹¹¹ were obtained from Mallinckrodt Medical, Inc. and Gd¹⁵³ was obtained

from Amersham. Other inorganic salts and solvents were obtained in the highest purity available.

UV-visible spectra were recorded on a Hewlett-Packard diode array spectrophotometer. DTPA dianhydride and 5'-chloro-5'-deoxyadenosine
5 were synthesized as described by W.C. Eckelman et al., J. Pharm. Sci., 64, 704 (1975) and K. Kikugawa et al., Tetrahedron Lett., 87 (1971), respectively. The monocarboxylic acids of cyanocobalamin, methylcobalamin-b-carboxylic acid and adenosylcobalamin-b-carboxylic acid were prepared and isolated as described by H.P.C. Hogenkamp, Biochemistry, 13, 2736 (1974); D.L. Anton et
10 al., J. Amer. Chem. Soc., 102, 2215 (1980); R.H. Yamada et al., J. Biol. Chem., 247, 6266 (1972) and D. Dolphin, Methods in Enzymology, Xville, 34-52 (1971). Methylcobalamin, adenosylcobalamin and their derivatives are light sensitive, especially in solution, and all reactions and manipulations were carried out in the dark or in dim light.

15 All images for the *in vivo* studies were obtained on a GE 500 maxicamera using a LEAP collimator with a 20% window about the 140 keV energy peak of technetium, and a medium energy collimator with a 20% window about the 174 keV and 247 keV energy peaks of Indium. A 256x256 matrix with a dedicated pinnacle computer system was used to collect and analyze the data.

20

Example 1. Cyanocobalamin-b-(4-aminobutyl)amide. A mixture containing cyanocobalamin-b-carboxylic acid (1.0 g, 0.6 mmol), hydroxybenzotriazole (0.81 g, 6 mmol) and 1,4-diaminobutane dihydrochloride (4.8 g, 30 mmol) in 100 ml of water was adjusted to pH 7.8. 1-Ethyl-3-(3'-
25 dimethylaminopropyl)carbodiimide (1.26 g, 6.6 mmol) was then added, the pH was adjusted to 6.4 and the reaction stirred at room temperature for 24 h. TLC on silica gel using *n*-butanol-acetic acid water (5:2:3) showed the reaction to be complete. Cyanocobalamin-b-(4-aminobutyl)amide was extracted into 92% aqueous phenol and the phenol layer was washed several times with equal
30 volumes of water. To the phenol extract were added 3 volumes of diethylether and 1 volume of acetone. The desired cobalamin was removed from the organic

phase by several extractions with water. The combined aqueous layers were extracted three times with diethylether to remove residual phenol, concentrated to approximately 20 ml *in vacuo* and crystallized from aqueous acetone. Yield 955 mg, 92%.

5

Example 2. Cyanocobalamin-b-(4-aminobutyl)amide DTPA. Cyanocobalamin-b-(4-aminobutyl) amide (500 mg, 0.3 mmol) was dissolved in 30 ml sat. sodium bicarbonate and treated with solid DTPA dianhydride (1.2 g, 3.4 mmol). The progress of the reaction was monitored by TLC on PEI plates using *n*-butanol-acetic acid-water (5:2:3) as the solvent. After 30 min incubation at room temperature a second 1.2 g of the dianhydride was added. After two additional additions of dianhydride with adjustments of the pH to 8.2 the reaction mixture was incubated overnight. Cyanocobalamin-DPTA adduct was then extracted into 92% aqueous phenol and purified as described above. The preparation was evaporated to dryness *in vacuo* and isolated as a glass. Yield 460 mg, 77%. The cyanobalamin-DTPA adduct behaves as a polyanion on paper electrophoresis in 0.1 M sodium phosphate buffer pH 7.1.

Example 3. Methylcobalamin-b-(4-aminobutyl)amide. Methylcobalamin-b-carboxylic acid (1.0 g, 0.6 mmol) was reacted with diaminobutane dihydrochloride as described above for the cyano derivative. The cobalamin was purified by extraction through phenol (see above) and the resulting aqueous solution was concentrated *in vacuo*. This solution was chromatographed on AG1-X2 200-400 mesh in the acetate form (20x 2.5 cm) and the pass through collected. The pass through was concentrated to approximately 20 ml and the desired cobalamin crystallized from aqueous acetone. Yield 920 mg, 88%. Unreacted methylcobalamin-b-carboxylic acid was eluted with 1 M acetic acid, concentrated and crystallized from aqueous acetone. Yield 60 mg, 6%.

Example 4. Methylcobalamin-b-(4-aminobutyl)amide DTPA. Methylcobalamin-b-(4-aminobutyl)amide (500 mg, 0.3 mmol) was dissolved in

30

30 ml saturated sodium bicarbonate and reacted with solid DTPA dianhydride as described above. The methyl cobalamin-DTPA adduct was purified by extraction through phenol, evaporated to dryness *in vacuo* and isolated as a glass. Yield 600 mg, 96%.

5

Example 5. Adenosylcobalamin-b-(4-aminobutyl)amide. Adenosylcobalamin-b-carboxylic acid (500 mg, 0.3 mmol) was reacted with diaminobutane dihydrochloride (2.4 mg, 15 mmol) as described above. The cobalamin was purified by extraction through phenol (see above). The resulting aqueous
10 solution was concentrated *in vacuo* and applied to AG-50 X2, 200-400 mesh, in the hydrogen form (20 x 25 cm). The column was washed thoroughly with water to remove hydroxybenzotriazole and the desired cobalamin eluted with 1 M ammonium hydroxide. After an additional extraction through phenol, adenosylcobalamin-b-(4-aminobutyl)amide was isolated as a glass. Yield 366
15 mg, 77%.

Example 6. Adenosylcobalamin-b-(4-aminobutyl)amide DTPA.

Adenosylcobalamin-b-(4-aminobutyl)amide (366 mg, 0.23 mmol) was dissolved in 30 ml saturated sodium bicarbonate and treated with solid DTPA dianhydride
20 (1.0 g, 2.8 mmol) as described above. The cobalamin was purified through phenol (see above). The resulting aqueous solution was concentrated and applied to AG-50 X2, 200-400 mesh, in the hydrogen form (6.0 x 2.5 cm), the column was washed with water and the desired cobalamin eluted with 0.1 M ammonium hydroxide. The solution was evaporated to dryness *in vacuo* and
25 adenosylcobalamin-b-(4-aminobutyl)amide DTPA isolated as a glass. Yield 400 mg, 80%.

Example 7. Interaction with Intrinsic Factor and Transcobalamin Proteins.

Under dim light, 1000 µg of the non-labeled methyl-, adenosyl-, and
30 cyanocobalamin-b-(4-aminobutyl)amide-DTPA, as well as 1000 µg of cyanocobalamin and DTPA (Sigma, St. Louis, MO 63178), were separately

dissolved in 10 ml of normal saline at room temperature. Each of the five 1000 μ g/10 ml samples were stored in sealed, aluminum-wrapped 10 ml vials to prevent exposure to light. No buffers were added to the solutions. The pH of the solutions, measured by a Beckman 40 pH meter (Beckman Instruments, Fullerton, CA): Cyanocobalamin = 5.75, DTPA = 3.78; cyano, methyl and adenosylcobalamin-DTPA analogues were 5.75, 6.10, and 6.19, respectively.

To assess *in vitro* binding to Intrinsic Factor (IF) and Transcobalamins (TC), the intrinsic factor blocking antibody (IFBA) and Unsaturated vitamin B₁₂ Binding Capacity (UBBC) assays were performed with serum randomly obtained from five patients being evaluated for pernicious anemia at the Mayo Clinic. The IFBA and UBBC assays were first performed for clinical purposes as previously described by V.F. Fairbanks et al., Mayo Clin. Proc., 58, 203 (1983); Intrinsic Factor Blocking Antibody [⁵⁷Co] Radioassay-Package insert, Diagnostic Products Corp.; D. Grossowicz et al., Proc. Exp. Biol., 109, 604 (1962) and C. Gottlieb et al., Blood, 25, 6 (1965).

Next, the serum from the same five patients underwent modified IFBA and UBBC assays. Specifically, 1 μ l of the five previously described solutions were separately incubated with purified IF or serum, to potentially saturate all IF and TC binding sites. After incubation for 20 minutes at room temperature and for another 20 minutes at 4°C, 500 μ l of the stock (1000 μ g/l) Cobalt-57-cyanocobalamin (Mallinckrodt Medical, Inc., St. Louis, MO 63134) solution was added and the usual IFBA and UBBC protocols were then followed. All supernatant activity was counted for four minutes on a gamma counter (Micromedix 10/20, Huntsville, AL 35805). The results are shown in Table I.

Table 1

UBBC						
	Clinical Run	CNB ₁₂	MEB ₁₂ DTPA	ADB ₁₂ DTPA	CNB ₁₂ DTPA	DTPA
PT1	741	<NSB	17.1	54.6	222.6	731.5
PT2	632	<NSB	26.8	62.6	216.9	913.1
PT3	2097	<NSB	278.9	590.3	713.3	2078.9
PT4	1378	<NSB	60.9	126.9	433.2	1633.7
PT5	1682	<NSB	91.1	163.9	643.2	1418.0

IFBA						
	Clinical Run	CNB ₁₂	MEB ₁₂ DTPA	ADB ₁₂ DTPA	CNB ₁₂ DTPA	DTPA
PT1	11942.5 (0.99)	951.5 (12.48)	4279 (2.77)	6758.5 (2.30)	5151 (2.30)	11899 (0.99)
PT2	11656 (1.02)	920.5 (12.90)	4082 (2.92)	6841.5 (1.74)	5133.5 (2.31)	11696.5 (1.02)
PT3	11780 (1.01)	912.5 (13.01)	4456.5 (2.66)	6828.5 (1.74)	5338.5 (2.22)	11735.5 (1.01)
PT4	11617 (1.02)	749 (15.85)	4414 (2.69)	7046.5 (1.64)	6002.5 (1.98)	11909 (1.00)
PT5	11653.5 (1.02)	858.5 (10.91)	4381.5 (2.77)	7096.5 (1.72)	5973.5 (1.99)	11778.5 (1.02)

NSB = Nonspecific binding; counts < 100 consistent with saturation of transcobalamin proteins

Negative reference for IFBA; no binding to intrinsic factor (< 1.11)

Positive reference for IFBA; binding to intrinsic factor (> 1.43)

Indeterminate reference value (1.11 - 1.43)

Clinical Run = patients supernatant counts from UBBC and IFBA assays

DTPA = diethylenetriamine pentaacetic acid

CNB₁₂ = cyanocobalamin

MEB₁₂DTPA = methylcobalamin-b-(4-aminobutyl)-amide-DTPA

ADB₁₂DTPA = adenosylcobalamin-b-(4-aminobutyl)-amide-DTPA

CNB₁₂DTPA = cyanocobalamin-b-(4-aminobutyl)-amide-DTPA

The IFBA assay demonstrated that DTPA does not significantly bind to IF (values less than the negative reference), whereas cyanocobalamin and the cobalamin-DTPA analogs do, in varying degrees, competitively inhibit Co-57 cyanocobalamin from binding to intrinsic factor. By using the counts of the Clinical run divided into the counts of the five solutions, the efficacy of binding to intrinsic factor can be estimated. The averaged percent binding of the five solutions to IF was: cyanocobalamin = 92.5%; methylcobalamin-b-(4-aminobutyl)-amide-DTPA = 63.2%; cyanocobalamin-b-(4-aminobutyl)-amide-DTPA = 52.9%; adenosylcobalamin-b-(4-aminobutyl)-amide-DTPA = 41.0% and 0.8% for DTPA. This is in contrast to the disclosure in Houts (U.S. Pat. No. 4,465,775) that the (b)-monocarboxylic acid of vitamin B₁₂ and its radioiodinated derivative exhibit very low binding to IF.

Likewise the averaged percent binding of the five solutions to the transcobalamin proteins was: cyanocobalamin = 100%, methylcobalamin-b-(4-aminobutyl)amide-DTPA = 94.0%, adenosylcobalamin-b-(4-aminobutyl)amide-DTPA = 90.4%, cyanocobalamin-b-(4-aminobutyl)amide-DTPA = 66.4% and 3.6% for DTPA.

Thus, the attachment of DTPA to vitamin B₁₂ does alter its binding to the carrier proteins. As expected, non-labeled cyanocobalamin had the greatest affinity for IF and the transcobalamin proteins. Methylcobalamin-b-(4-aminobutyl)amide-DTPA was next, followed by adenosylcobalamin-b-(4-aminobutyl)amide-DTPA, and finally cyanocobalamin-b-(4-aminobutyl)amide-DTPA. There was also some nonspecific binding of DTPA to the carrier proteins (0.8% and 3.6%).

25

Example 8. Chelation of Radionuclides. Under dim light, 1000 µg of methyl-, adenosyl-, and cyanocobalamin-b-(4-aminobutyl)amide-DTPA were separately dissolved in 200 µl of normal saline. Next, 500 µCi of Indium-111 or 250 µCi of Gadolinium-153 were added to the cobalamin-DTPA solutions. The reactions were carried out at room temperature and room air. For the chelation of technetium, the dissolved cobalamin DTPA complexes were separately placed

30

into sealed 2 ml vials. Next, 200 μ l of stannous chloride solution (1000 μ g/ml normal saline) were added to each vial. The vials were purged with nitrogen gas for 5 minutes. After this time, 1-5 mCi of Technetium-99m was added to the N₂ purged vials. Each vial underwent further nitrogen purging for 5 minutes. All
5 chelation reactions were mixed gently for 5 minutes.

Control mixtures of 1000 μ g of cyanocobalamin were dissolved in 200 μ l of normal saline. Cyanocobalamin was mixed with Tc-99m at room temperature and room air, as well as within nitrogen purged vials containing 200 μ l of the described stannous chloride solution. Additionally, the cobalamin-
10 DTPA complexes underwent Tc-99m labeling in open vials at room air in the absence of the stannous chloride.

Specific activity was assessed by mixing 100 μ l aliquots of methyl and adenosyl cobalamin-b-(4-aminobutyl)amide-DTPA (5 μ g/100 μ l normal saline) with 50 μ l stannous chloride solution (1 μ g/50 μ l normal saline)
15 in nitrogen purged 2 ml vials. Technetium-99m in 10, 25, 50, 75, and 100 mCi allotments of activity were added to the vials. The vials underwent gentle mixing and continuous nitrogen purging for five minutes after the addition of technetium.

Efficiency of chelation and specific activity were assessed via thin
20 layer chromatography (TLC). Thin layer chromatographic strips (Grade 31 ET Chr-thickness 0.50 mm, flow rate (water) 225 mm/30 min, Whatman Lab Sales, Hilsboro, OR 97123) were developed in acetone in dim light. The dry strips were placed on film (Ektascan-MC1, Eastern Kodak, Rochester, NY 14650) for autoradiography (AR). Chromatographic and autoradiographic results were
25 visually compared. All the radiolabeled cobalamin-DTPA complexes underwent TLC and AR to confirm 100% labeling prior to *in vivo* administration.

Under acetone development, free Tc-99m migrates to the top of the chromatographic strip, whereas In-111 and Gd-153 diffusely spread over the lower two-thirds of the strip. TLC and AR analysis demonstrated that there was
30 100% labeling of all three cobalamin-DTPA complexes with Tc-99m, In-111,

and Gd-153. Specifically, all radioactivity was confined to the chromatographic distribution of the cobalamin analogues.

Since methyl and adenosyl cobalamin could potentially have greater uptake in malignant tissue, the chelation of Tc-99m, In-111, and Gd-153 by methyl and adenosylcobalamin-b-(4-aminobutyl)amide-DTPA underwent greater scrutiny. The chromatographic and autoradiographic images were consistently coincident. In contrast, unmodified cyanocobalamin did not demonstrate any affinity for binding the three radionuclides. As expected, there was minimal labeling of the cobalamin-DTPA complexes with Tc-99m in the absence of stannous chloride and hypoxic conditions.

At a concentration of 5 µg/100 µl the red color of the cobalamin-DTPA analogues is barely discernible in the aqueous state, and undetectable on TLC. However, the AR distribution is the same when compared to the more concentrated cobalamin analogue solutions with lower specific activity. Methyl and adenosyl cobalamin-b-(4-aminobutyl)amide-DTPA can chelate up to 50 mCi of technetium-99m per 5 µg with 100% efficiency. This results in a specific activity of 10 mCi/µg for the cobalamin-DTPA analogue.

Example 9. In Vivo Studies.

A. Biodistribution: Methylcobalamin-b-(4-aminobutyl)amide-DTPA in a concentration of 300 µg/100 µl normal saline was labeled with 3 mCi of Indium-111. The labeled vitamin B₁₂ analogue was diluted with normal saline to a final volume of 1000 µl. Via intraperitoneal injection (IP), five 12 week old female Balb-C mice (Harlan, Sprague, Dawley, Indianapolis, IN 46229) each received 200 µl (500 µCi) of the methylcobalamin-DTPA-¹¹¹In complex. For comparison, Indium-111-DTPA having the same concentration and specific activity of the methylcobalamin-DTPA analogue, was injected IP into three mice. All mice were sacrificed at 24 hours via CO₂ inhalation. The pancreas, spleen, kidneys, and heart were dissected in their entirety. A portion of the liver, lung, left quadricep muscle, and flank fat were also harvested. All tissue samples and organs were weighed wet, minced in 2.0 ml normal saline, and

counted for five minutes in a gamma well counter (Minaxi Autogamma 5000, Packard Instrument, Downers Grove, IL 60515).

B. Gastrointestinal Absorption: Methylcobalamin-b-(4-aminobutyl)-DTPA and DTPA alone were labeled as described above, with the exception that
5 the 3 mCi Indium/300 µg/100 µl normal saline solutions were not diluted. Two groups of three mice had a few drops of either ¹¹¹In-DTPA or methylcobalamin-b-(4-aminobutyl)-DTPA-In-111 placed in their oral cavities. The mice were sacrificed at 24 hrs, dissected, and studied as described above.

A modified Schillings test was performed on two mice.

10 Specifically, each mouse received via subcutaneous and intraperitoneal administration, a 1000 µg loading dose of non-labeled methylcobalamin-b-(4-aminobutyl)amide-DTPA analogue. At 24 hrs, the mice were fed 2-3 drops of Indium-labeled methylcobalamin-b-(4-aminobutyl)amide-DTPA-complex. Urine and feces were collected from the three groups of mice after oral
15 administration. The mice were sacrificed at 24 hours after ingestion of tracer and images and biodistribution data were obtained at that time.

C. Tumor Imaging: At 24 hours, there was a significant amount of adenosylcobalamin-b-(4-aminobutyl) amide-DTPA-In-111 uptake within the transplanted sarcoma both visually and by gamma well counting (Table II).

Table II

	Kidney	Liver	Spleen	Pancreas	Heart	Lung	Fat	Muscle	Tumor
Mouse 1	3717.5	943.3	433.1	304.2	134.7	130.9	101.4	93.6	—
Mouse 2	3299.5	823.4	405.3	319.9	189.4	180.1	147.3	51.4	—
Mouse 3	3462.7	768.6	366.8	310.3	171.2	113.1	102.8	43.9	—
Mouse 4	224.0	56.9	44.1	13.4	10.3	6.2	12.6	5.4	—
Mouse 5	130.2	41.5	26.2	13.0	6.9	6.0	19.5	5.6	—
Mouse 6	281.6	66.1	57.7	14.1	12.5	10.5	18.8	5.0	—
Mouse 7	621.4	126.4	67.8	40.0	35.0	38.4	—	13.6	—
Mouse 8	700.5	111.7	66.6	39.3	29.8	51.2	—	12.4	—
Mouse 9	601.7	115.8	66.3	41.2	31.3	40.6	—	12.0	—
Mouse 10	119.4	24.0	19.5	6.0	5.6	5.4	—	8.9	—
Mouse 11	117.3	25.5	19.0	6.7	5.0	5.3	—	2.6	—
Mouse 12	110.1	23.2	18.1	5.9	4.8	5.0	—	3.7	—
Mouse 13	4.3	0.82	0.67	0.75	0.54	1.1	< BKG	< BKG	—
Mouse 14	4.1	0.80	0.70	0.76	0.54	0.33	< BKG	< BKG	—
Mouse 15	3.1	0.73	0.65	1.1	0.50	0.44	< BKG	< BKG	—
Mouse 16	0.64	0.28	0.62	0.93	< BKG	< BKG	< BKG	< BKG	—
Mouse 17	0.54	0.21	0.67	0.96	< BKG	< BKG	< BKG	< BKG	—
Mouse 18	0.59	0.30	0.48	0.61	< BKG	< BKG	< BKG	< BKG	—
Mouse 19	3886.9	691.0	576.3	445.0	165.0	318.8	76.0	70.1	954.7
Mouse 20	3115.6	464.8	309.5	242.7	134.8	230.0	170.4	81.9	1426.0
Mouse 21	3592.8	675.0	478.3	439.0	157.8	335.2	198.0	166.5	1183.1
Mouse 22	116.5	19.7	17.3	7.1	5.0	4.5	13.7	7.2	52.8
Mouse 23	180.7	40.9	22.8	11.3	8.0	9.2	17.9	6.4	69.3
Mouse 24	231.2	60.3	46.1	13.9	9.7	8.5	19.2	6.8	73.1
Mouse 25	543.9	116.5	54.7	38.4	21.7	34.4	39.5	23.5	135.5
Mouse 26	240.8	56.2	25.8	21.3	11.4	19.9	13.5	15.5	60.4
Mouse 27	459.2	107.6	37.1	30.3	16.9	21.3	17.8	14.5	120.3
Mouse 28	14.0	1.6	1.9	1.4	0.94	1.7	0.93	.68	5.0
Mouse 29	9.9	1.3	1.4	8.2	0.61	0.87	0.75	.60	2.8
Mouse 30	10.2	1.4	1.6	3.1	0.85	0.93	0.79	.63	3.4

Mice 1-3 and 19-21 = 500 μ Ci adenosylcobalamin-b-(4-aminobutyl)-amide-DTPA-¹¹¹In injected intraperitoneal

Mice 4-6 and 22-24 = 500 μ Ci DTPA-¹¹¹In injected intraperitoneal

Mice 7-9 = 500 μ Ci adenosylcobalamin-b-(4-aminobutyl)-amide-DTPA-¹¹¹In injected subcutaneously

Mice 10-12 = 500 μ Ci DTPA-¹¹¹In injected subcutaneously

Mice 13-15 = approximately 30 μ Ci methylcobalamin-b-(4-aminobutyl)-amide-DTPA-¹¹¹In administered orally

Mice 16-18 = approximately 30 μ Ci DTPA-¹¹¹In administered orally

Mice 25-27 = approximately 100 μ Ci methylcobalamin-b-(4-aminobutyl)-amide-DTPA-¹¹¹In tailvein injection

Mice 28-30 = approximately 100 μ Ci DTPA-¹¹¹In tailvein injection

Despite the difference in the amount of activity injected between IP and IV routes, the degree of uptake within the tumor was consistently second behind the kidneys. The tumors had two to four times greater activity than the liver, spleen, and pancreas, with 4-12 times greater activity than that of the heart, lungs, fat, and muscle. As expected, no activity was seen to localize in the left flank of the control mice. Usual uptake in the liver and spleen was again seen. Gross pathology of the dissected masses demonstrated fat encapsulated tumors. Microscopically, by H & E stain, the tumors were solid masses of blue stained cells consistent with a sarcoma. No areas of necrosis were noted.

Although DTPA-¹¹¹In demonstrated uptake within the transplanted tumors, its concentration was 10-20 times less than that of adenosylcobalamin-DTPA-¹¹¹In.

D. Intravenous Administration: One milligram of either methyl or adenosylcobalamin-b-(4-aminobutyl)amide-DTPA was labeled with 5 mCi of ^{99m}Tc as described above. Several mice were sacrificed via CO₂ inhalation at varying time intervals after tailvein injection. The first urine passed was collected and analyzed via TLC and AR.

E. Results

1. In Vivo Studies

20 (a) Biodistribution

The organ and tissue distribution of the methyl and adenosylcobalamin-DTPA analogs at 24 hours was similar despite the route of administration (Table II). The kidneys were first, followed by the liver and spleen. The pancreas usually was next followed by the lungs, fat, heart, and muscle. The differences in activity between the pancreas, heart, lung, fat, and muscle was less significant after oral, subcutaneous, and intravenous administration. However, the ratio of uptake between the kidneys to liver, liver to spleen, and spleen to pancreas was relatively constant. The route of administration (IV, IP, PO) did not have any obvious effect on the chelation of Tc-99m or In-111 by these complexes.

The greatest amount of DTPA-¹¹¹In uptake was in the kidneys. The distribution of DTPA was similar to the cobalamin analogs, especially after intraperitoneal injection. Despite their similarities, DTPA-¹¹¹In had 5-12 times less activity per organ or tissue sample when compared to the methyl and
5 adenosylcobalamin analogs.

(b) Gastrointestinal Absorption

Methylcobalamin-b-(4-aminobutyl) amide-DTPA-In-111 was absorbed from the gastrointestinal tract after oral administration. The majority of activity was localized in the kidneys, liver, and spleen on delayed imaging. In the mice
10 that were not "flushed" with oral and intraperitoneal doses of non-labeled methylcobalamin-b-(4-aminobutyl) amide-DTPA, no discernable activity was detected in the urine by gamma well counting. However, the mice that underwent the "modified Schillings test" had detectable radioactivity within their urine at one hour. Imaging at 24 hours of these "flushed" mice demonstrated
15 significantly less activity throughout the body when compared to the "non-flushed" mice. Fecal radioactivity became detectable at 2 hours in both groups receiving the radioactive cobalamin analogs orally.

DTPA-¹¹¹In was also absorbed from the gastrointestinal tract, but to a lesser degree. No activity was detected in the heart, lungs, muscle, or fat
20 tissue samples. Radioactivity was detected in urine and stool by two hours.

(c) Intravenous Administration

Micturition occurred at approximately 15 and 45 minutes after intravenous and intraperitoneal injections, respectively. The first passed urine after intravenous or intraperitoneal administration was always radioactive. TLC
25 and AR analysis of the collected urine showed no evidence of dissociation of the Tc-99m or In-111 from the cobalamin-DTPA complexes. Images at 5 minutes and 4 hours after tailvein injection demonstrated focal early uptake in the kidneys which became obscured by the liver and spleen activity on the delayed images.

(d) Tumor Imaging

At 24 hours, there was a significant amount of adenosylcobalamin-b-(4-aminobutyl) amide-DTPA-In-111 uptake within the transplanted sarcoma both visually and by gamma well counting (Table II).


- 5 Despite the difference in the amount of activity injected between IP and IV routes, the degree of uptake within the tumor was consistently second behind the kidneys. The tumors had two to four times greater activity than the liver, spleen, and pancreas, with 4-12 times greater activity than that of the heart, lungs, fat, and muscle. As expected, no activity was seen to localize in the left flank of the
- 10 control mice. Usual uptake in the liver and spleen was again seen. Gross pathology of the dissected masses demonstrated fat encapsulated tumors. Microscopically, by H & E stain, the tumors were solid masses of blue stained cells consistent with a sarcoma. No areas of necrosis were noted.

- Although DTPA-¹¹¹In demonstrated uptake within the
- 15 transplanted tumors, its concentration was 10-20 times less than that of adenosylcobalamin-DTPA-¹¹¹In.


- The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while
- 20 remaining within the scope of the invention.

CLAIMS

- 1) The use of a compound having the following formula:



wherein the moiety



is cobalamin;



is the carbonyl residue of a cobalamin amido group;


X is CN, OH, methyl or adenosyl;

Y is a linking group; and

Det is a chelating group comprising a therapeutic radionuclide; in combination with a pharmaceutically acceptable carrier, in the making of a medication for treating a mammal inflicted with a tumor.


- 2) The use of claim 1 wherein the therapeutic radionuclide is Yttrium-90 or Rhenium-186.
- 3) The use of claim 1 wherein $\text{C}(=\text{O})$ is the residue of a (b)-propionamide of cobalamin.
- 4) The use of claim 1 wherein $\text{C}(=\text{O})$ is the residue of a (d)-propionamide of cobalamin.
- 5) The use of claim 1 wherein Y is a divalent monomer, a divalent dimer, or a divalent trimer of $\text{H}_2\text{N}(\text{CH}_2)_{2-6}\text{NH}_2$; $\text{HO}(\text{CH}_2)_{2-6}\text{OH}$; $\text{HO}_2\text{C}(\text{CH}_2)_{2-6}\text{CO}_2\text{H}$; $\text{H}_2\text{N}(\text{CH}_2)_{2-6}\text{OH}$; $\text{H}_2\text{N}(\text{CH}_2)_{2-6}\text{CO}_2\text{H}$; or $\text{HO}(\text{CH}_2)_{2-6}\text{CO}_2\text{H}$.

- 6) The use of claim 1 wherein Y is $-N(H)(CH_2)_4 NH-$.
- 7) The use of claim 1 wherein the chelating group is ethylenediaminetetraacetic acid; diethylenetriaminepentaacetic acid (DTPA); 1,4,7,10-tetraazacyclododecane- N,N',N'',N''' -tetraacetic acid (DOTA); 1,4,8,11-tetraazacyclotetradecane- N,N',N'',N''' -tetraacetic acid (DOTA); 1,4,8,12-tetraazacyclopentadecane- N,N',N'',N''' -tetraacetic acid (15N4); 1,4,7-triazacyclononane- N,N',N'' -triacetic acid (9N3); 1,5,9-triazacyclododecane- N,N',N'' -triacetic acid (12N3); 2-p-nitrobenzyl-1,4,7,10-tetraazacyclododecane- N,N',N'',N''' -tetraacetic acid; 6-bromoacetamido-benzyl-1,4,8,11-tetraazacyclotetradecane- N,N',N'',N''' -tetraacetic acid (BAT); or a cyclohexane-based metal chelator (DCTA) of the formula




- wherein R^3 may be (C_1-C_4) alkyl or $CH_2CO_2^-$, which may be attached through positions 4 or 5, or through the group R^3 and which carries from 1 to 4 detectable metal or nonmetal canons (M), monovalent cations, or the alkaline earth metals; or a pharmaceutically acceptable salt thereof.
- 8) The use of claim 1 wherein the chelating group is DTPA.
 - 9) The use of claim 1 wherein the tumor is located in the gastrointestinal tract, liver, kidney, pancreas, or spleen.
 - 10) The use of claim 1, wherein the medication is parenteral.
 - 11) The use of claim 1, wherein the medication is intravenous.
 - 12) The use of claim 1, wherein the medication is intraperitoneal.
 - 13) The use of claim 1, wherein the medication is oral.

- 14) The use of a compound having the following formula:



wherein the moiety



is cobalamin;



is a carbonyl residue of a cobalamin amido group;


X is CN, OH, methyl or adenosyl;

Y is a linking group; and

Det is a chelating group comprising a detectable radionuclide; in combination with a pharmaceutically acceptable carrier, in the making of a diagnostic composition for imaging tumors in mammals and detecting the presense of the compound therein.

- 15) The use of claim 14 wherein the detectable radionuclide is $\text{Tc}^{99\text{m}}$, In^{111} , or Gd^{153} .
- 16) The use of claim 14 wherein $\text{C}(=\text{O})$ is the residue of a (b)-propionamide of cobalamin.
- 17) The use of claim 14 wherein $\text{C}(=\text{O})$ is the residue of a (d)-propionamide of cobalamin.
- 18) The use of claim 14 wherein Y is a divalent monomer, a divalent dimer, or a divalent trimer of $\text{H}_2\text{N}(\text{CH}_2)_{2-6}\text{NH}_2$; $\text{HO}(\text{CH}_2)_{2-6}\text{OH}$; $\text{HO}_2\text{C}(\text{CH}_2)_{2-6}\text{CO}_2\text{H}$; $\text{H}_2\text{N}(\text{CH}_2)_{2-6}\text{OH}$; $\text{H}_2\text{N}(\text{CH}_2)_{2-6}\text{CO}_2\text{H}$; or $\text{HO}(\text{CH}_2)_{2-6}\text{CO}_2\text{H}$.
- 19) The use of claim 14 wherein Y is $-\text{N}(\text{H})(\text{CH}_2)_4\text{NH}-$.


- 20) The use of claim 14 wherein the chelating group is ethylenediaminetetraacetic acid; diethylenetriaminepentaacetic acid (DTPA); 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA); 1,4,8,11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid (TETA); 1,4,8,12-tetraazacyclopentadecane-N,N',N'',N'''-tetraacetic acid (15N4); 1,4,7-triazacyclononane-N,N',N''-triacetic acid (9N3); 1,5,9-triazacyclododecane-N,N',N''-triacetic acid (12N3); 2-p-nitrobenzyl-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid; 6-bromoacetamido-benzyl-1,4,8,11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid (BAT); or a cyclohexane-based metal chelator (DCTA) of the formula




wherein R^3 may be (C_1-C_4) alkyl or $CH_2CO_2^-$, which may be attached through positions 4 or 5, or through the group R^3 and which carries from 1 to 4 detectable metal or nonmetal canons (M), monovalent canons, or the alkaline earth metals; or a pharmaceutically acceptable salt thereof.

- 21) The use of claim 14 wherein the chelating group is DTPA.
- 22) The use of claim 14 wherein the tumor is located in the gastrointestinal tract, liver, kidney, pancreas, or spleen.
- 23) The use of claim 14, wherein the diagnostic composition is destined for is parenteral use.
- 24) The use of claim 14, wherein the diagnostic composition is destined for is intravenous use.
- 25) The use of claim 14, wherein the diagnostic composition is destined for is intraperitoneal use.
- 26) The use of claim 14, wherein the diagnostic composition is destined for is oral use.

- 27) The use of a compound having the following formula:



wherein the moiety




is cobalamin;



is the carbonyl residue of a cobalamin amido group, X is CN, OH, methyl or adenosyl, Y is a linking group and Det is a chelating group comprising a metallic radioisotope; in combination with a pharmaceutically acceptable vehicle, in the making of a composition for evaluating kidney, liver, spleen or intestinal function in a mammal and detecting the presence of said compound in the kidney, liver, pancreas, spleen, or intestine of said mammal.

- 28) The use of claim 27, wherein the composition is destined for is parenteral use.
- 29) The use of claim 27, wherein the composition is destined for is intravenous use.
- 30) The use of claim 27, wherein the composition is destined for is intraperitoneal use.
- 31) The use of claim 27, wherein the composition is destined for is oral use.
- 32) A method for preparing a compound of the formula:



wherein



is cobalamin;



is the carbonyl residue of a cobalamin amido group;

X is cyano, hydroxy, methyl, or adenosyl;


Y is a linking group; and

Chel is a chelating group;

the method comprising reacting a carboxyl substituent of cobalamin with a divalent bifunctional organic linking group; and


reacting the linking group with a chelating group to provide the compound.

- 33) The method of claim 32 wherein the carbonyl residue is derived from the (b)-propionamide group of cobalamin, the (d)-propionamide group of cobalamin, the (e)-propionamide group of cobalamin, or a mixture thereof.
- 34) The method of claim 32 wherein Y is a divalent monomer, dimer, or trimer of $\text{H}_2\text{N}(\text{CH}_2)_{2-6}\text{NH}_2$; $\text{HO}(\text{CH}_2)_{2-6}\text{OH}$; $\text{HO}_2\text{C}(\text{CH}_2)_{2-6}\text{CO}_2\text{H}$; $\text{H}_2\text{N}(\text{CH}_2)_{2-6}\text{CO}_2\text{H}$; or $\text{HO}(\text{CH}_2)_{2-6}\text{CO}_2\text{H}$.
- 35) The method of claim 32 wherein Chel is ethylenediaminetetraacetic acid; diethylenetriaminepentaacetic acid (DTPA); 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA); 1,4,8,11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid (TETA); 1,4,8,12-tetraazacyclopentadecane-N,N',N'',N'''-tetraacetic acid (15N4); 1,4,7-triazacyclononane-N,N',N''-triacetic acid (9N3); 1,5,9-triazacyclododecane-N,N',N''-triacetic acid (12N3); 2-p-nitrobenzyl-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid; 6-bromoacetamido-benzyl-1,4,8,11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid (BAT); or a cyclohexane-based metal chelator (DCTA) of the formula




wherein R^3 may be (C_1-C_4) alkyl or $CH_2CO_2^-$, which may be attached through positions 4 or 5, or through the group R^3 and which carries from 1 to 4 detectable metal or nonmetal cations (M), monovalent cations, or the alkaline earth metals; or a pharmaceutically acceptable salt thereof.

- 36) The method of claim 32 wherein Chel is diethylenetriaminepentaacetic acid (DTPA).
- 37) The method of claim 32 wherein the carboxyl substituent of cobalamin is obtained by hydrolyzing cobalamin.
- 38) A method for preparing a compound of formula (I):



wherein



is cobalamin;




is the carbonyl residue of a cobalamin amido group;

X is cyano, hydroxy, methyl, or adenosyl:

Y is a linking group; and


Det is a detectably labeled chelating group;

the method comprising reacting a compound of the formula:



wherein Chel is a chelating group, with a radionuclide or a paramagnetic metal ion.

- 39) The method of claim 38 wherein the radionuclide is a radioisotope metal ion.
- 40) The method of claim 39 wherein the radioisotope metal ion is a cation derived from a metal selected from the group consisting of $\text{Tc}^{99\text{m}}$, In^{111} , Yt^{90} , Re^{186} , and Gd^{153} .
- 41) The method of claim 38 wherein Y is a divalent monomer, dimer, or trimer of $\text{H}_2\text{N}(\text{CH}_2)_{2-6}\text{NH}_2$; $\text{HO}(\text{CH}_2)_{2-6}\text{OH}$; $\text{HO}_2\text{C}(\text{CH}_2)_{2-6}\text{CO}_2\text{H}$; $\text{H}_2\text{N}(\text{CH}_2)_{2-6}\text{OH}$; $\text{H}_2\text{N}(\text{CH}_2)_{2-6}\text{CO}_2\text{H}$; or $\text{HO}(\text{CH}_2)_{2-6}\text{CO}_2\text{H}$.
- 42) The method of claim 38 wherein Chel is ethylenediaminetetraacetic acid; diethylenetriaminepentaacetic acid (DTPA); 1,4,7,10-tetraazacyclododecane- $\text{N},\text{N}',\text{N}'',\text{N}'''$ -tetraacetic acid (DOTA); 1,4,8,11-tetraazacyclotetradecane- $\text{N},\text{N}',\text{N}'',\text{N}'''$ -tetraacetic acid (TETA); 1,4,8,12-tetraazacyclopentadecane- $\text{N},\text{N}',\text{N}'',\text{N}'''$ -tetraacetic acid (15N4); 1,4,7-triazacyclononane- $\text{N},\text{N}',\text{N}''$ -triacetic acid (9N3); 1,5,9-triazacyclododecane- $\text{N},\text{N}',\text{N}''$ -triacetic acid (12N3); 2-p-nitrobenzyl-1,4,7,10-tetraazacyclododecane- $\text{N},\text{N}',\text{N}'',\text{N}'''$ -tetraacetic acid; 6-bromoacetamido-benzyl-1,4,8,11-tetraazacyclotetradecane- $\text{N},\text{N}',\text{N}'',\text{N}'''$ -tetraacetic acid (BAT); or a




cyclohexane-based metal chelator (DCTA) of the formula

wherein R^3 may be $(\text{C}_1\text{-C}_4)\text{alkyl}$ or CH_2CO_2^- , which may be attached through positions 4 or 5, or through the group R^3 and which carries from 1 to 4 detectable metal or nonmetal cations (M), monovalent cations, or the alkaline earth metals; or a pharmaceutically acceptable salt thereof.

43) The method of claim 38 wherein Chel is diethylenetriaminepentaacetic acid (DTPA).

44) A compound of the formula:



wherein



is cobalamin;



is the carbonyl residue of a cobalamin amido group;

X is cyano, hydroxy, methyl, or adenosyl;

Y is a linking group; and

Chel is a chelating group;

or a pharmaceutically acceptable salt thereof.


45) The compound of claim 44 wherein the carbonyl residue is derived from the (b)-propionamide group of cobalamin, the (d)-propionamide group of cobalamin, the (e)-propionamide group of cobalamin, or a mixture thereof.

46) The compound of claim 44 wherein Y is a divalent monomer, a divalent dimer, or a divalent trimer of $\text{H}_2 \text{N}(\text{CH}_2)_{2-6} \text{NH}_2$; $\text{HO}(\text{CH}_2)_{2-6} \text{OH}$; $\text{HO}_2 \text{C}(\text{CH}_2)_{2-6} \text{CO}_2 \text{H}$; $\text{H}_2 \text{N}(\text{CH}_2)_{2-6} \text{OH}$; $\text{H}_2\text{N}(\text{CH}_2)_{2-6}\text{CO}_2\text{H}$; or $\text{HO}(\text{CH}_2)_{2-6}\text{CO}_2\text{H}$.

47) The compound of claim 44 wherein Y is $\text{---N(H)(CH}_2)_4 \text{NH---}$.


48) The compound of claim 44 wherein the chelating group is ethylenediaminetetraacetic acid; diethylenetriaminepentaacetic acid (DTPA); 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA); 1,4,8,11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid (TETA); 1,4,8,12-tetraazacyclopentadecane-N,N',N'',N'''-tetraacetic acid (15N4); 1,4,7-triazacyclononane-N,N',N''-triacetic acid (9N3); 1,5,9-

triazacyclododecane-N,N',N''-triacetic acid (12N3); 2-p-nitrobenzyl- 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid; 6-bromoacetamido-benzyl-1,4,8,11 -tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid (BAT); or a cyclohexane-based metal chelator (DCTA) of the formula



wherein R^3 may be (C_1-C_4) alkyl or $CH_2CO_2^-$, which may be attached through positions 4 or 5, or through the group R^3 and which carries from 1 to 4 detectable metal or nonmetal canons (M), monovalent cations, or the alkaline earth metals; or a pharmaceutically acceptable salt thereof.

- 49) The compound of claim 44 wherein the chelating group is DTPA.
- 50) The compound of claim 44, formulated for parenteral use.
- 51) The compound of claim 44, formulated for intravenous use.
- 52) The compound of claim 44, formulated for intraperitoneal use.
- 53) The compound of claim 44, formulated for oral use.
- 54) A compound of the formula (1)



wherein the moiety



is cobalamin;




is the carbonyl residue of a cobalamin amido group;

X is CN, OH, methyl or adenosyl;

Y is a linking group; and

Det is a chelating group comprising a therapeutic or detectable radionuclide, or a paramagnetic metal ion; in combination with a pharmaceutically acceptable carrier.


- 55) The compound of claim 54 wherein the chelating group is a radioisotope metal ion.
- 56) The compound of claim 55 wherein the radioisotope metal ion is a cation derived from a metal selected from the group consisting of Tc^{99m}, In¹¹¹, Yt⁹⁰, Re¹⁸⁶, and Gd¹⁵³.
- 57) The compound of claim 54 wherein the carbonyl residue is derived from the (b)-propionamide group of cobalamin, the (d)-propionamide group of cobalamin, the (e)-propionamide group of cobalamin, or a mixture thereof.
- 58) The compound of claim 54 wherein Y is a divalent monomer, a divalent dimer, or a divalent trimer of H₂ N(CH₂)₂₋₆ NH₂; HO(CH₂)₂₋₆ OH; HO₂ C(CH₂)₂₋₆ CO₂ H; H₂ N(CH₂)₂₋₆ OH; H₂N(CH₂)₂₋₆CO₂H; or HO(CH₂)₂₋₆CO₂H.
- 59) The compound of claim 54 wherein Y is -N(H)(CH₂)₄ NH-.
- 60) The compound of claim 54 wherein the chelating group is ethylenediaminetetraacetic acid; diethylenetriaminepentaacetic acid (DTPA); 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA); 1,4,8,11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid (TETA); 1,4,8,12-tetraazacyclopentadecane-N,N',N'',N'''-tetraacetic acid (15N4); 1,4,7-triazacyclononane-N,N',N''-triacetic acid (9N3); 1,5,9-triazacyclododecane-N,N',N''-triacetic acid (12N3); 2-p-nitrobenzyl- 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid; 6-bromoacetamido-benzyl- 1,4,8,11 -tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid (BAT); or a cyclohexane-based metal chelator (DCTA) of the formula



wherein R^3 may be (C_1-C_4) alkyl or $CH_2CO_2^-$, which may be attached through positions 4 or 5, or through the group R^3 and which carries from 1 to 4 detectable metal or nonmetal cations (M), monovalent cations, or the alkaline earth metals; or a pharmaceutically acceptable salt thereof.

- 61) The compound of claim 54 wherein the chelating group is DTPA.
- 62) The compound of claim 54, formulated for parenteral administration.
- 63) The compound of claim 54, formulated for intravenous administration.
- 64) The compound of claim 54, formulated for intraperitoneal administration.
- 65) The compound of claim 54, formulated for oral administration.

Figure 1



2/2

Figure 2

